What is virtual inventory in 340B?
Virtual inventory is a way to run 340B without keeping a separate shelf of 340B drugs. The pharmacy dispenses from its regular stock, software checks afterward which uses were for 340B-eligible patients, and those units are tallied by drug and package size. When eligible use adds up to a full package, the covered entity reorders that exact product at the 340B price, and the new stock simply refills the shelf. The 340B inventory is “virtual” because it exists as a running balance in the records, not as separate bottles. HRSA has described replenishment models as permissible as long as every 340B order traces back to earlier use by eligible patients.[1][3]
Buy at a regular price → dispense → accumulate eligible use → replenish at the 340B price.
Four steps, repeated every day
The 340B price shows up on the reorder, not on the drug that was given to the patient.
- 1
Stock the shelf at a non-340B price
A virtual inventory starts with neutral stock bought on a regular account (for hospitals subject to the GPO prohibition, typically WAC). Nothing on the shelf is labeled 340B.[5][11]
- 2
Dispense or administer
Patients get the drug from that one shared inventory. Whether a given use counts as 340B is decided after the fact, from the claim or charge and the encounter behind it.[1]
- 3
Qualify and accumulate
Software applies your eligibility rules and adds each qualifying unit to a balance for that drug and package. Ineligible and inpatient use goes to other accounts.[1][10]
- 4
Replenish at the 340B price
Once the 340B balance equals an available package size, a 340B order is placed and the balance is drawn down. On arrival the drug loses its identity and is just stock again.[1]
HRSA’s own short definition: replenishment is “a process by which a covered entity reorders drug inventory based on actual prior drug usage.” For the account-by-account mechanics in a hospital, see 340B accumulators and split billing.[1]
Physical vs. virtual 340B inventory
The two can be combined: a separate physical stock in one setting and a virtual inventory in another. Apexus training calls this a hybrid model.
| Physical (separate) inventory | Virtual (replenishment) inventory | |
|---|---|---|
| What sits on the shelf | 340B drugs kept apart from other stock, in their own bins or a separate location. | One shared inventory. 340B status lives in the accumulator balance, not on the bottle.[1][10] |
| When 340B status is decided | Before dispensing: staff pick from the 340B stock for an eligible patient. | After dispensing: the use is qualified, then accumulated toward a 340B reorder.[1] |
| Where it fits | Settings where 340B stock can be kept apart and dispensed only to patients already known to be eligible. | Mixed-use hospital areas and most contract pharmacies, where patient status isn’t known at the shelf.[4][10] |
| Start-up | Buy 340B stock up front for expected eligible use. | Buy neutral stock on a regular account first; 340B purchases only follow eligible use.[5][11] |
| Main compliance risk | 340B units given to an ineligible patient, or physical counts that don’t match records. | Units accumulated that shouldn’t have been, or 340B orders larger than the eligible balance.[1][8] |
| What proves it | Dispensing logs and periodic physical counts tied to 340B invoices. | Claim-level accumulation records tied to each 340B purchase, NDC by NDC.[1][7] |
Either way, HRSA’s proposed 2015 guidance treated a gap between the recorded and actual number of 340B drugs as a potential diversion problem, whether the entity kept a virtual or a separate physical inventory.[1][13]
The same idea, across two companies
At a contract pharmacy, eligibility depends on your prescribers, locations and patient records, so the claim is qualified after it’s filled and the 340B purchase follows.
Pharmacy fills from its own stock
The contract pharmacy dispenses the prescription and bills the payer as usual.
TPA qualifies the claim
The claim is matched to your eligible prescribers and locations and, if it qualifies, accumulated for that pharmacy.
Order on your account
When a package is reached, a 340B order is placed in the covered entity’s name. The wholesaler bills the covered entity.
Shipped to the pharmacy
The replacement ships straight to the pharmacy and refills its shelf. That’s the ship-to, bill-to arrangement.
HRSA’s 2010 guidance says the covered entity purchases the drug, keeps title and sets its price, and that the manufacturer or wholesaler bills the covered entity but ships directly to the contract pharmacy. It also says inventory and record segregation is one of many methods to stay compliant, and that HRSA doesn’t intend to limit the methods entities use.[3]
HRSA recommends reconciling dispensing, purchasing and billing records as part of contract pharmacy oversight. See how contract pharmacy setup works with a TPA.[6]
The four states of a virtual inventory balance
Every drug, package and account has a running balance. Here’s what each state means for savings and for compliance.
Accumulating
Eligible units are building but haven’t reached a full package. Nothing can be ordered at the 340B price yet. HRSA’s sample audit request still counts these units in your 340B universe.[1][7]
Ready to order
The balance covers at least one package of that exact product. A 340B order can be placed, and whatever is left over carries forward.[1]
Unreplenished and aging
Eligible use that never turns into an order, often slow movers or partial packages. It means savings you aren’t capturing, and the units still sit in your 340B universe with records to support them. Re-labeling old purchases as 340B after the fact (“banking”) is a different practice HRSA cautioned against.[1][7][11]
HRSA’s 2015 proposal also said that accumulating a unit that shouldn’t count is a problem even before any order is placed, and that entities should return unused or expired 340B drugs and account for waste, backed by written procedures for reconciling discrepancies.[1]
Common causes, and the four ways to fix them
Causes
- Unit and package conversion
In one Apexus case study, an EHR charge-mapping change recorded each dose from a multi-dose vial as a full package, inflating accumulations until 340B purchases outran eligibility.[8]
- NDC changes and shortages
Replenishment is matched on the product actually used. When buyers switch NDCs or vial sizes during a shortage, the accumulator has to be updated or balances drift.[8][10]
- Reversals and eligibility errors
Reversed claims and bad eligibility data sent to the 340B vendor are common sources of ineligible 340B purchases.[9]
- Lost charges and waste
If a use never generates a charge, or waste isn’t accumulated, the replacement gets bought on a higher-priced account instead of 340B.[11]
- Manual adjustments
Hand edits to balances are sometimes needed, but each one should be documented so the purchase trail still holds up.[8][10]
Fixes
- 1
- 2
- 3
- 4
In the Apexus case study, one charge-mapping error touched 30 NDCs and left 23 with negative balances; the team returned 7, rebilled 10 and repaid manufacturers directly for 6.[8]
What HRSA asks about virtual inventory
- Item H of the data request: how you account for 340B inventory, physical or virtual replenishment.[7]
- A 340B universe that includes every accumulation designated as 340B, replenished or not.[7]
- Claim-level fields for each use, including the NDC, quantity and the account it was purchased on.[7]
- Someone who can navigate the split-billing or third-party software during testing.[7]
The statute requires covered entities to let HRSA and manufacturers audit records that pertain to diversion and duplicate discounts, so the accumulator history is part of your compliance file. For the full audit process, see how to prepare for a HRSA 340B audit.[13]
What HRSA has said about replenishment, and what still applies
- 2010Contract pharmacy notice
Sets the ship-to, bill-to arrangement and says inventory and record segregation is only one of many acceptable methods. HRSA does not limit how entities stay compliant.[3]
- 2013GPO prohibition release 2013-1
Said a hospital subject to the GPO prohibition that orders on actual prior usage can’t tally 340B-ineligible outpatient use for orders on a GPO account. A federal court vacated it on March 31, 2026, and HRSA’s policy page now marks it vacated.[1][12]
- 2015Proposed omnibus guidance
Described replenishment models in the most detail HRSA has published: order only on actual prior eligible use, package-size reorders, auditable records for every 340B order. It was withdrawn in January 2017 and never finalized.[1][2]
- OngoingHRSA FAQs
Hospitals need a tracking system to use 340B in mixed-use areas, auditable records of what accumulated where, and a non-GPO account for when a 340B product isn’t available.[4][5]
- TodayAudit data request
HRSA’s audit data request asks whether you use physical or virtual inventory and includes unreplenished accumulations in the 340B universe.[7]
Virtual inventory you can see and defend
Real-time capture and splitting
Claims are captured and purchases split as they happen, so balances stay current and there are no end-of-month true-ups.
Audit-ready by default
Claim-level history behind every replenishment, duplicate discount monitoring and a dedicated account manager when an auditor asks for your 340B universe. See the reports a TPA should provide.
Contract pharmacy and split billing
We run contract pharmacy and split billing for 300 covered entities, 24 of them hospitals, across a network of 10,000+ pharmacies.
Ready for 2027 rebates
The rebate module is Included for Aventi TPA clients, with real-time 340B ESP and Truzo (Kalderos) integration. Learn about the 2027 340B rebate model.
340B virtual inventory: common questions
Sources
- Federal Register, 340B Drug Pricing Program Omnibus Guidance (proposed), 80 FR 52300 (Aug. 28, 2015), Drug Inventory/Replenishment Models and Part C sections — https://www.federalregister.gov/documents/2015/08/28/2015-21246/340b-drug-pricing-program-omnibus-guidance
- OIRA (reginfo.gov), 340B Program Omnibus Guidelines, RIN 0906-AB08, concluded action: withdrawn (Jan. 30, 2017) — https://www.reginfo.gov/public/do/eoDetails?rrid=126712
- Federal Register, Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 FR 10272 (Mar. 5, 2010), comment responses and essential element (a) — https://www.federalregister.gov/documents/2010/03/05/2010-4755/notice-regarding-340b-drug-pricing-program-contract-pharmacy-services
- HRSA FAQ, May a hospital use 340B-priced drugs in “mixed-use” settings … if the hospital cannot track which drugs are used for inpatients and which ones are used for outpatients? — https://www.hrsa.gov/about/faqs/may-hospital-use-340b-priced-drugs-mixed-use-settings-such-surgery-department-where-both-inpatients
- HRSA FAQ, Our mixed-use area has only inpatients or 340B eligible outpatients … is it required to start with a WAC inventory? — https://www.hrsa.gov/about/faqs/our-mixed-use-area-has-only-inpatients-or-340b-eligible-outpatients-we-do-not-have-any-340b
- HRSA FAQ, What are the audit and compliance parameters under the contract pharmacy guidelines? — https://www.hrsa.gov/about/faqs/what-are-audit-compliance-parameters-under-contract-pharmacy-guidelines
- 340B Prime Vendor Program (Apexus), Sample HRSA 340B Audit Data Request List for Covered Entities (item H and 340B universe instructions) — https://www.340bpvp.com/Documents/Public/340B%20Tools/sample-hrsa-340b-audit-data-request-for-covered-entities.pdf
- Apexus, Case study: Fixing 340B Inventory Errors Due to EHR Billing Corrections — https://www.apexus.com/about-us/articles-and-updates/fixing-340b-inventory-errors-due-to-ehr-billing-corrections
- Apexus, Expert Tip: Resolve Negative 340B Accumulations (published in 340B Report, Nov. 30, 2023) — https://www.apexus.com/about-us/articles-and-updates/expert-tip-resolve-negative-340b-accumulations
- Apexus, 340B Certificate Program Curriculum (Replenishment and Separate Physical Inventory Models; Split-Billing Software Maintenance and Compliance; Contract Pharmacy Inventory Management) — https://www.apexus.com/340b-certificate-program/resources/program-curriculum
- Pharmacy Times, Minimizing WAC Exposure to Decrease Drug Expense in the Virtual Inventory Setting — https://www.pharmacytimes.com/view/minimizing-wac-exposure-to-decrease-drug-expense-in-the-virtual-inventory-setting
- HRSA, 340B Policy Releases (Release 2013-1 marked vacated by Premier, Inc. v. HRSA, No. 24-cv-3116, D.D.C. Mar. 31, 2026) — https://www.hrsa.gov/opa/program-requirements/policy-releases
- 42 U.S.C. § 256b(a)(5)(B)–(C) (diversion; auditable records) (Cornell LII) — https://www.law.cornell.edu/uscode/text/42/256b
- HRSA Office of Pharmacy Affairs, Program Integrity (self-disclosure, corrective action, manufacturer repayment) — https://www.hrsa.gov/opa/program-integrity
Last updated November 19, 2026. This page is general information, not legal advice. Check HRSA’s current guidance and your own counsel for your program.